Propensity score analysis: Frontline therapy with hyper-CVAD (HCVAD) plus ponatinib vs. HCVAD plus dasatinib in patients (pts) with Philadelphia chromosome-positive (Ph plus ) acute lymphoblastic leukemia (ALL).

被引：1
|
作者：
Sasaki, Koji
Kantarjian, Hagop M.
Ravandi, Farhad
Thomas, Deborah A.
Daver, Naval Guastad
Kadia, Tapan M.
Konopleva, Marina
Jain, Nitin
Short, Nicholas James
Issa, Ghayas C.
Jeanis, Vicky
Moore, H. Gal
Garris, Rebecca S.
Garcia-Manero, Guillermo
Cortes, Jorge E.
O'Brien, Susan Mary
Jabbour, Elias
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Univ Calif Irvine, Irvine, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.7025
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7025
引用
收藏
页数：4
相关论文
共 50 条
  • [31] Discontinuation of Tyrosine Kinase Inhibitors (TKIs) in Philadelphia Chromosome-Positive (Ph plus ) Acute Lymphoblastic Leukemia (ALL)
    Samra, Bachar
    Kantarjian, Hagop M.
    Sasaki, Koji
    Konopleva, Marina Y.
    Khouri, Rita
    O'Brien, Susan M.
    Ferrajoli, Alessandra
    Nunez, Cesar
    Kadia, Tapan M.
    Jabbour, Elias
    BLOOD, 2019, 134
  • [32] Phase II study of combination of hyperCVAD with ponatinib in frontline therapy of patients (pts) with Philadelphia chromosome (Ph) positive acute lymphoblastic leukemia (ALL).
    Jabbour, Elias
    Kantarjian, Hagop M.
    Thomas, Deborah A.
    Ravandi, Farhad
    Cortes, Jorge E.
    Faderl, Stefan
    Pemmaraju, Naveen
    Kadia, Tapan M.
    Garris, Rebecca S.
    Garcia-Manero, Guillermo
    Borthakur, Gautam
    Wierda, William G.
    O'Brien, Susan Mary
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [33] Phase II study of combination of hyperCVAD with ponatinib in frontline therapy of patients (pts) with Philadelphia chromosome (Ph) positive acute lymphoblastic leukemia (ALL).
    O'Brien, Susan Mary
    Jabbour, Elias
    Thomas, Deborah A.
    Ravandi, Farhad
    Cortes, Jorge E.
    Pemmaraju, Naveen
    Kadia, Tapan M.
    Garris, Rebecca
    Jeanis, Vicky
    Garcia-Manero, Guillermo
    Borthakur, Gautam
    Wierda, William G.
    Kantarjian, Hagop M.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [34] A Phase 1/2 Study to Evaluate the Safety and Efficacy of Ponatinib with Chemotherapy in Pediatric Patients with Philadelphia Chromosome-Positive (Ph plus ) Acute Lymphoblastic Leukemia (ALL)
    Matloub, Yousif
    Gore, Lia
    Loh, Mignon L.
    Pui, Chin-Hon
    Hanley, Michael J.
    Lu, Vickie
    Leonard, E. Jane
    Granier, Muriel
    Biondi, Andrea
    Silverman, Lewis B.
    BLOOD, 2020, 136
  • [35] Phase II study of combination of the hyperCVAD regimen with dasatinib in patients (pts) with newly diagnosed Philadelphia chromosome positive (Ph plus ) acute lymphoblastic leukemia (ALL)
    Ravandi, F.
    Faderl, S.
    Thomas, D. A.
    Brown, D.
    Garris, R.
    Borthakur, G.
    Ferrajoli, A.
    Cortes, J. E.
    Kantarjian, H. M.
    O'Brien, S. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [36] A phase II trial of a chemotherapy-free combination of ponatinib and blinatumomab in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph plus ALL).
    Short, Nicholas James
    Kantarjian, Hagop M.
    Konopleva, Marina
    Bravo, Guillermo Montalban
    Ravandi, Farhad
    Jain, Nitin
    Kadia, Tapan M.
    Valero, Yesid Alvarado
    Chien, Kelly Sharon
    Daver, Naval Guastad
    Macaron, Walid
    Sasaki, Koji
    Thankachan, Jennifer
    Delumpa, Ricardo
    Mayor, Ejiroghene
    Deen, Wuliamatu
    Loiselle, Christopher
    Kwari, Monica
    Garris, Rebecca
    Jabbour, Elias
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [37] Ponatinib vs. Imatinib as Frontline Treatment for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Matching Adjusted Indirect Comparison
    Ribera, Josep-Maria
    Prawitz, Thibaud
    Freitag, Andreas
    Sharma, Anuj
    Dobi, Balazs
    Rizzo, Federica
    Sabatelli, Lorenzo
    Patos, Petros
    ADVANCES IN THERAPY, 2023, 40 (07) : 3087 - 3103
  • [38] Outcome of Patients (Pts) with Philadelphia Chromosome-Positive (Ph plus ) Acute Lymphoblastic Leukemia (ALL) without 3-Month Complete Molecular Response (CMR)
    Samra, Bachar
    Kantarjian, Hagop M.
    Sasaki, Koji
    Short, Nicholas J.
    Khouri, Rita
    Khoury, Joseph D.
    Champlin, Richard E.
    Kebriaei, Partow
    Cortes, Jorge E.
    Jorgensen, Jeffrey L.
    Wang, Sa A.
    Garcia-Manero, Guillermo
    Kadia, Tapan M.
    Borthakur, Gautam M.
    Verstovsek, Srdan
    Daver, Naval G.
    Montalban-Bravo, Guillermo
    Jain, Nitin
    Konopleva, Marina Y.
    Yilmaz, Musa E.
    Naqvi, Kiran
    O'Brien, Susan M.
    Ravandi, Farhad
    Jabbour, Elias
    BLOOD, 2019, 134
  • [39] Ponatinib Versus Imatinib with Reduced-Intensity Chemotherapy in Patients with Newly Diagnosed Philadelphia Chromosome-Positive (Ph plus ) Acute Lymphoblastic Leukemia (ALL): PhALLCON Study
    Jabbour, Elias
    Martinelli, Giovanni
    Vignetti, Marco
    Kantarjian, Hagop
    Gomez-Almaguer, David
    Minami, Yosuke
    Dombret, Herve
    Hennessy, Meliessa
    Vorog, Alexander
    Wang, Bingxia
    Ribera, Josep-Maria
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S269 - S269
  • [40] Ponatinib vs. Imatinib as Frontline Treatment for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Matching Adjusted Indirect Comparison
    Josep-Maria Ribera
    Thibaud Prawitz
    Andreas Freitag
    Anuj Sharma
    Balázs Dobi
    Federica Rizzo
    Lorenzo Sabatelli
    Petros Patos
    Advances in Therapy, 2023, 40 : 3087 - 3103
12345